Automate Your Wheel Strategy on DSGN
With Tiblio's Option Bot, you can configure your own wheel strategy including DSGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DSGN
- Rev/Share 0.0103
- Book/Share 3.7467
- PB 1.3745
- Debt/Equity 0.0052
- CurrentRatio 25.1279
- ROIC -0.3485
- MktCap 293282715.0
- FreeCF/Share -0.8931
- PFCF -5.7757
- PE -4.6123
- Debt/Assets 0.0049
- DivYield 0
- ROE -0.2715
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
DSGN
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025
Read More
About Design Therapeutics, Inc. (DSGN)
- IPO Date 2021-03-29
- Website https://www.designtx.com
- Industry Biotechnology
- CEO Pratik Shah
- Employees 56
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.